

Statin use and the risk of developing diabetes: a network meta-analysis

Divyesh Thakker, Sunita Nair*, Amit Pagada, Vinayak Jamdade and Anuradha Malik

Knowledge Services (Health Research & Consulting), Capita, India

ABSTRACT

Purpose Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta-analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices.

Methods We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre-2010 studies were identified from bibliography of previously published meta-analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta-analysis and NMA within a Frequentist framework.

Results Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non-diabetic patients. The direct meta-analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05–1.21; I^2 36%; $p=0.002$; 18 RCTs). In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14–1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02–1.35). The ORs (95%CIs) for simvastatin 80 mg, simvastatin, atorvastatin, pravastatin, lovastatin and pitavastatin were 1.21 (0.99–1.49), 1.13 (0.99–1.29), 1.13 (0.94–1.34), 1.04 (0.93–1.16), 0.98 (0.69–1.38) and 0.74 (0.31–1.77), respectively. High-dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low-dose atorvastatin in the NMA.

Conclusions Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta-analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.

KEY WORDS—safety; statins; cardiovascular disease; type 2 diabetes; systematic review; meta-analysis; network meta-analysis; pharmacoepidemiology

Received 23 July 2015; Revised 14 March 2016; Accepted 01 April 2016

INTRODUCTION

Cardiovascular diseases (CVDs) are a major cause of illness and death worldwide. Elevated blood cholesterol levels, specifically the low-density lipoprotein (LDL) cholesterol, are associated with a higher risk of heart attack, stroke and heart failure.¹ Several studies have shown that correction of dyslipidaemia significantly decreases the risk of CVD events.^{2,3} Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors) are one of the mainstays of treatment and widely used for lowering cholesterol for the prevention of CVD.⁴ Beyond their LDL-lowering effects, statins due to their pleiotropic effect also reduce vascular inflammation,

improve endothelial function and decrease thrombus formation.^{5–7}

It has been known that statins can modulate insulin secretion and sensitivity.^{8,9} However, recent findings from some randomized controlled trials (RCTs) showed that statins can raise blood sugar, and more patients on statin therapy were diagnosed with diabetes mellitus. The Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin¹⁰ and Prospective Study of Pravastatin in the Elderly at Risk¹¹ trials found that patients randomized to rosuvastatin and pravastatin, respectively developed, a significantly higher incidence of type 2 diabetes compared with placebo. Conversely, results from the West of Scotland Coronary Prevention Study¹² showed that pravastatin therapy might reduce the frequency of diabetes. This led researchers to conduct several systematic literature reviews and

*Correspondence to: S. Nair, Knowledge Services (Health Research & Consulting), Capita India Pvt. Ltd., Godrej and Boyce Compound, Gate 2A, LBS Marg, Vikhroli (West) 400079 Mumbai, India. Email: Sunita.Nair@capita.co.uk

meta-analyses to assess the contradicting findings of these trials. Sattar *et al.*¹³ conducted a meta-analysis of 13 RCTs and concluded that statin therapy was associated with a 9% increased risk for incidence of diabetes. Two years later, the same finding was reported by Mills *et al.*¹⁴ within a pooled estimate of 17 RCTs. Researchers have also conducted network meta-analyses (NMA) of RCTs to investigate the impact of different types and doses of statins on new-onset diabetes.^{15–17}

Although Sattar *et al.*¹³ and Mills *et al.*¹⁴ were concurrent in their findings that statin use significantly increases the risk of diabetes mellitus; these studies derived the pooled estimate with the statin class as a whole, rather than individual statins. Moreover, these studies analysed only the direct evidence. Such analyses often undermine even the beneficial effects of some statins that have been shown to reduce the incidence of diabetes.^{12,18,19} Alberton *et al.* conducted a meta-analysis and also evaluated indirect comparisons to identify differing risk effects across statins; however, they did not provide sufficient evidence for diabetes in the indirect comparisons.¹⁵ Navarese *et al.*¹⁶ and Naci *et al.*¹⁷ both employed NMA methodology for evaluating the association of statin use and diabetes, but these reviews did not include published or unpublished evidence for pitavastatin.

With the current controversy on the utility of statins and the associated risks, well-researched evidence becomes imperative to accurate clinical decision making. Randomized controlled trials are more frequently conducted to evaluate efficacy endpoints rather than adverse reactions. Therefore, RCTs are not sufficiently powered to detect differences in safety outcomes, unlike real-world observational studies. However, as NMA combine the direct and indirect estimates, it may yield a more refined and precise estimate for the interventions directly compared and broaden inference with the population sampled. We aimed to use NMA to assess the direct and indirect evidence from published and unpublished studies to bring forth valuable evidence about statins and their association with diabetes mellitus.^{10–12}

METHODS

Type of studies, participants, and intervention

Randomized controlled trials, published in English, that used any of the statins for CVDs and specified incidence of diabetes were evaluated for inclusion. Trials unclear for allocation concealment and method of randomization, and open label studies were also

included but quality of these studies was taken into consideration. Quasi-randomized trials and nonrandomized studies were excluded.

Identification of studies

We identified the studies, relevant to our NMA by performing study searches in databases like Embase, Cochrane and PubMed published between August 2010 and June 2014. We identified the studies prior to August 2010 from the bibliography of previously published systematic literature reviews and meta-analyses.^{13,14} We also looked for unpublished trials from clinicaltrials.gov.

Two researchers evaluated the results of the search strategy to identify potentially relevant trials and retrieved the full-text articles. Both researchers independently assessed each of these trials for inclusion in the review using an eligibility form based on the review inclusion criteria. We resolved any disagreements by discussion, with referral to a third researcher, if required.

Two reviewers independently entered data into a data extraction form. We collected data on study characteristics, including methods, participants, interventions and outcomes. Any disagreement was resolved by referring to the trial report and through discussion and consultation with the third reviewer.

Risk of bias assessment

The risk of bias (RoB) was assessed for each included study using the Cochrane Collaboration criteria.²⁰ These included random sequence generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data and selective outcome reporting. As selective reporting was not relevant to our review, we removed it from the RoB summary figure. The RoB of each study was explicitly judged on each criterion and classified as 'low', 'high' or 'unclear'. To summarize the overall RoB for a study, we considered randomization, allocation concealment, blinding and monitoring and detection of diabetes in order to classify each study as 'low risk of bias' when all four criteria were met; 'high risk of bias' when none of the criteria were met; and 'moderate risk of bias' in the remaining cases. For detection of diabetes, we judged study at 'low' RoB if reviewers used any international standard criteria or used two fasting glucose values ≥ 7.0 mmol/L. If it was detected using only one value or diabetes was identified as spontaneous reporting only, we judged the study as 'high' RoB. The RoB of each study was assessed

independently by the two reviewers and any disagreement was resolved by discussion to reach consensus.

Data synthesis

For each pairwise comparison and each outcome at each time point, we used odds ratio (OR) with 95% confidence interval (95%CI) as a measure of the association between the treatment used and efficacy. If the outcomes were negative, ORs < 1 corresponded to beneficial treatment effects of the first treatment compared with the second treatment.

Heterogeneity or inconsistency can be the result of an uneven distribution of important clinical and methodological effect modifiers across studies (heterogeneity) or across comparisons (inconsistency). The presence of statistical heterogeneity was assessed by visual inspection of the forest plots and by calculating the I^2 statistic and its confidence limits. Wherever significant heterogeneity was detected, we perform the meta-regression analysis to explore the source of heterogeneity. Potential sources of heterogeneity or inconsistency include different participant baseline characteristics, different treatment dose and influence of funders.

First, conventional pairwise meta-analyses was conducted for all outcomes and comparisons, provided that at least two studies were available, using a random-effects model.²¹ We performed the pairwise meta-analysis using RevMan 5.1[®]. We then performed a NMA for incidence of diabetes mellitus within a Frequentist framework, assuming an equal heterogeneity parameter τ () across all comparisons.

It is essential to check the assumptions of the analysis before drawing conclusions while using NMA methodology. The most important assumption is that the network of comparisons is consistent, such that direct and indirect evidence on the same comparisons agree. Joint analysis can be misleading if the network is substantially inconsistent. Inconsistency can be present if the trials in the network have very different protocols and their inclusion and exclusion criteria are not comparable, or may result from an uneven distribution of effect modifiers across groups of trials that compare different treatments. In order to estimate network inconsistency, we calculated the difference between indirect and direct estimates in each closed-loop formed by the network of trials (using the Bucher method) and their relative 95%CI. We then examined whether there were any material discrepancies; if the 95%CI did overlap with 1 the hypothesis of consistency was not rejected, as described in Salanti *et al.*²²

In order to assess the presence of small-study effects, we used the funnel plot. The application of the funnel plots in NMA need to account for the fact that studies estimate effects for different comparison. Therefore, to judge the symmetry, a single reference line cannot be used. To account for the different summary effect with each set of studies, Chaimani *et al.* suggested the use of 'comparison-adjusted' funnel plot.²³ In the 'comparison-adjusted' funnel plot, the horizontal axis presents the difference between the study-specific effect sizes from the corresponding comparison-specific summary effect.

We used the STATA 12.0[®] routines to perform all the analyses based on Chaimani *et al.*²³

RESULTS

Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagram is represented in Figure 1. Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non-diabetic patients. The duration of the trials ranged from 3 months to 6.1 years, with the median duration being 4.8 years. Mean age of the patients ranged from 53 to 75 years in the studies. The body mass index (BMI) and LDL-cholesterol levels ranged from 23 to 31 kg/m² and 97 to 192 mg/dL, respectively among the studies. Majority of the studies reported the use of other cardiovascular medications. Tables 1 and 2 provide details on the characteristics of the included studies.

Risk of bias in the included studies

The RoB of the included studies is summarized in Figures S1 and S2. Considering our predefined criteria (randomisation, allocation concealment, blinding and based on detection of diabetes) to assess the RoB, four of the 29 studies were judged at low,^{10,24–26} and the remaining 25 at moderate RoB. None of the studies were judged at high RoB.

Risk of developing diabetes

Pairwise meta-analysis (direct comparisons). Of the 29 trials^{10–12,18,19,24–47} directly comparing statin versus placebo or any other active agent, 16 trials^{10–12,18,19,25–29,32–35,37,39} compared one of the statins (atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin) versus placebo or usual care, two^{31,38} compared any statin versus no




Figure 1. Preferred reporting items for systematic reviews and meta-analyses flow diagram

statin treatment and seven trials^{24,30,36,40,41,44,45} compared intensive statin treatment versus moderate statin treatment. Four of the seven pitavastatin trials compared pitavastatin to other statins.^{42,43,46,47} Of the 18 trials comparing statin with control, only four^{10,11,38,39} showed that statin significantly increased the risk of developing diabetes.

The meta-analysis derived that, statins significantly increased the likelihood of developing diabetes to 12% (pooled OR 1.12; 95%CI 1.05–1.21; I^2 36%; $p=0.002$; 18 RCTs) in the random-effects model (Figure 2). Only rosuvastatin was shown to increase the risk of developing diabetes significantly ([pooled OR 1.18; 95%CI 1.04–1.33; I^2 0%; $p=0.009$; 4 RCTs] Figure 2).

STATINS AND RISK OF DIABETES

Table 1. Characteristics of included studies

Study name	Country (ies)	Study design	Study duration
PMSGCRP 1993 ²⁷	Australia, Belgium, Finland, Germany, Israel, Sweden, UK Norway	RCT, double-blind	3.1 years
4S 1994 ²⁸	US	RCT, double-blind	5.4 years
Downs 1998 (AFCAPS/TEXCAPS) ³³	US	RCT, double-blind	5.2 years
GISSI PREV 2000 ¹⁹	Italy	RCT, open-label	3.2 years
Freeman 2001 (WOSCOPS) ¹²	UK	RCT, double-blind	4.8 years
ALLHAT 2002 ²⁹	US, Puerto Rico, US Virgin Islands, and Canada	RCT, open-label	4.8 years
Saito 2002 ⁴⁵	Japan	RCT, double-blind	12 weeks
Shepherd 2002 (PROSPER) ¹¹	Scotland, Ireland, and Netherlands	RCT, double-blind	3.2 years
Collins 2003 (HPS) ²⁵	UK, Ireland, Norway, Sweden	RCT, double-blind	5 years
Keech 2003 (LIPID) ¹⁸	Australia (67 centres) and New Zealand (20 Centres)	RCT, double-blind	6.1 years
Pedersen 2005 (IDEAL) ⁴⁰	Norway, Sweden, Iceland, Denmark, Finland, Netherland International	RCT, Open label, blinded end-point	4.8 years
Amarenco 2006 (SPARCL) ³⁹	Japan	RCT, double-blind	4.9 years
Nakamura 2006 (MEGA) ³⁵	Japan	RCT, open-label	5.3 years
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	19 European countries, Russia, and South Africa	RCT, double-blind	Median 32.8 months (2.7 years)
Ridker 2008 (Jupiter; NCT00239681) ¹⁰	Multicountry	RCT, double-blind	60 months (5 years)
Tavazzi 2008 (GISSI HF) ²⁶	Italy	RCT, double-blind	3.9 years
Budinski 2009 ⁴²	International	RCT, double-blind	12 weeks
Ose 2009 ⁴⁶	International	RCT, double-blind	12 weeks
Athyros 2010 (GREACE) ³¹	Greece	RCT, open label, survival study	3 years
Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	Canada	RCT, double-blind	3.5 years
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	UK	RCT, double-blind	Mean: 6.7 (SD1.5) person-years
Collier 2011 (ASCOT-LLA) ³⁷	UK	RCT, double-blind	Median 3.3 years
Nozue 2012 (TRUTH) ⁴⁴	Japan	RCT, open label	32 weeks
Chen 2013 ²⁴	14 countries	RCT, double-blind	3.5 months
Kurogi 2013 (COMPACT-CAD) ⁴³	Japan	RCT, open label	2.3 years
Shen 2013 (NCT0097786; NAVIGATOR) ³⁸	38 countries	Re-analysis-NAVIGATOR trial	Median 5.0 years
NK-104-4-01CH ⁴⁷	China	RCT, open label	12 weeks
Ong 2014 (TNT) ³⁶	Australia	RCT, double-blind	Median 4.9 years
INTREPID ⁴¹	USA	RCT, double-blind	12/52 weeks

NR = not reported; RCT = randomised controlled trial; IQR = interquartile range; SE = standard error; SD = standard deviation; ERN/LRPT = Extended-release niacin/laropiprant; IFG = impaired fasting glucose.

Table 1. Characteristics of included studies

Study name	Study groups	No. of patients	Age, Mean (SD), years
PMSCGRP 1993 ²⁷ 4S 1994 ²⁸	Pravastatin 20 mg vs placebo Simvastatin vs placebo	530 vs 532 2221 vs 2223	55 (range: 20–86) vs 55 (range: 22–77) Men: 58.2 (7.3) vs 58.1 (7.2) Women: 60.5 (6.4) vs 60.5 (5.7) 58.0 (7.0) vs 58.0 (7.0) 59.3 55.3 (5.5) vs 55.1 (5.5) 66.4 (7.6) vs 66.3 (7.5) 20–75 75.4 (3.3) vs 75.3 (3.4) <65: 85% vs 20% 65–70: 84% vs 12% Median (IQR): 62 (55–67) vs 62 (55–68) 61.8 (9.5) vs 61.6 (9.5)
Downs 1998 (AFCAPS/TEPCAPS) ³³ GISSI PREV 2000 ¹⁹ Freeman 2001 (WOSCOPS) ¹² ALLHAT 2002 ²⁹ Saito 2002 ⁴⁵ Shepherd 2002 (PROSPER) ¹¹ Collins 2003 (HPS) ²⁵ Keech 2003 (LIPID) ¹⁸	Lovastatin vs placebo Pravastatin vs usual care Pravastatin 40 mg vs placebo Pravastatin vs usual care Pitavastatin 2 mg vs pravastatin 10 mg Pravastatin vs placebo Simvastatin 40 mg vs placebo Pravastatin vs placebo	3304 vs 3301 2138 vs 2133 3302 vs 3293 5170 vs 5185 240 2891 vs 2913 10 269 vs 10 267 4512 vs 4502	4439 vs 4449
Pedersen 2005 (IDEAL) ⁴⁰	Atorvastatin 80 mg vs simvastatin 20–40 mg	2365 vs 2366 3866 vs 3966 2514 vs 2497	63.0 (0.2) vs 62.5 (0.2) 58.2 (7.3) vs 58.4 (7.2) 73 (7.1) vs 73 (7.0)
Amarengo 2006 (SPARCL) ³⁹ Nakamura 2006 (MEGA) ³⁵ Kjekshus 2007 (NCT00206310; CORONA) ³⁴ Ridker 2008 (Jupiter; NCT00239681) ¹⁰ Tavazzi 2008 (GISSI HF) ²⁶ Budinski 2009 ⁴² Ose 2009 ⁴⁶	Atorvastatin vs placebo Rosuvastatin vs placebo Pitavastatin 2–4 mg vs atorvastatin 10–20 mg Pitavastatin 2–4 mg vs simvastatin 20–40 mg Statin vs no statin Rosuvastatin vs placebo Simvastatin 80 mg vs 20 mg	8901 vs 8901 2285 vs 2289 616 vs 205 631 vs 217 880 vs 720 134 vs 135 6031 vs 6033	Median 66 vs 66 68 (11) vs 68 (11) 58.3 (9.6) 58.7 (8.8)
Athyros 2010 (GREACE) ³¹ Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³² Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	Atorvastatin vs placebo (>=65 years) Atorvastatin vs placebo (<65 years) Pitavastatin 4 mg vs pravastatin 20 mg ERN/LRPT + Simvastatin 20 vs ERN/LRPT + Simvastatin 40 Atorvastatin 10 vs 20 vs 40 vs 80	2189 vs 2256 2979 vs 2881 58 vs 61 297 vs 436 298 vs 439 vs 437 vs 433 65 vs 64	<60: 406/1880 vs 424/1885 >=60 to <70: 574/2414 vs 601/2414 >=70: 497/1737 vs 528/1734 71.1 (4.1) vs 71.1 (4.0) 57.2 (5.6) vs 57.0 (5.7) 67 54.1 (10.8) vs 55.0 (10.3)
Collier 2011 (ASCOT-LLA) ³⁷ Nozue 2012 (TRUTH) ⁴⁴ Chen 2013 ²⁴	Pitavastatin 2–4 mg vs atorvastatin 10–20 mg Statins vs no Statins	1353 vs 4793	53.7 (10.6) vs 54.8 (10.8) vs 55.1 (10.1) vs 54.7 (10.5) 68.4 (9.1) vs 68.9 (10.2)
Kurogi 2013 (COMPACT-CAD) ⁴³ Shen 2013 (NCT00097786; NAVIGATOR) ³⁸ NK-104-4-01CH ⁴⁷ Ong 2014 (TNT) ³⁶ INTREPID ⁴¹	Pitavastatin 4 mg vs atorvastatin 20 mg Atorvastatin 10 mg vs 80 mg Pitavastatin 4 mg vs pravastatin 40 mg	476 5006 vs 4995 123 vs 124	Median (range): 63 (58–68) vs 63 (58–68) 18–75 60.9 (8.8) vs 61.2 (8.8) 18–65

NR = not reported; RCT = randomised controlled trial; IQR = interquartile range; SE = standard error; SD = standard deviation; ERN/LRPT = Extended-release niacin/laropiprant; IFG = impaired fasting glucose.

STATINS AND RISK OF DIABETES

Table 1. Characteristics of included studies

Study name	Gender, Female; n (%)	Ethnicity; n (%)
PMSGCRP 1993 ²⁷	119 (23) vs 128 (24)	NR
4S 1994 ²⁸	407 (18) vs 420 (19)	NR
Downs 1998 (AFCAPS/TEXCAPS) ³³	499 (15) vs 498 (15)	White: 2925 (89) vs 2935 (89) Black: 105 (3) vs 101 (3) Hispanic: 247 (7) vs 240 (7)
GISSI PREV 2000 ¹⁹	13.7%	NR
Freeman 2001 (WOSCOPS) ¹²	NR	White, non-Hispanic: 2107 vs 2129 Black, non-Hispanic: 1769 vs 1722
ALLHAT 2002 ²⁹	2511 (48.6) vs 2540 (49.0)	White, Hispanic: 759 vs 803 Black, Hispanic: 210 vs 181 Other: 325 vs 350
Saito 2002 ⁴⁵	NR	NR
Shepherd 2002 (PROSPER) ¹¹	1495 (51.71) vs 1505 (51.66)	White: 6358 vs 6325 Black: 1100 vs 1124
Collins 2003 (HPS) ²⁵	0.82 vs 0.16	Hispanic: 1121 vs 1140 Other: 322 vs 312
Keech 2003 (LIPID) ¹⁸	756 (17) vs 760 (17)	NR
Pedersen 2005 (IDEAL) ⁴⁰	849 (19.1) vs 852 (19.2)	NR
Amarenco 2006 (SPARCL) ³⁹	938 (39.7) vs 970 (41)	NR
Nakamura 2006 (MEGA) ³⁵	2638 (68) vs 2718 (69)	NR
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	593 (24) vs 587 (24)	NR
Ridker 2008 (Jupiter; NCT00239681) ¹⁰	3426 (38.5) vs 3375 (37.9)	White: 6358 vs 6325 Black: 1100 vs 1124 Hispanic: 1121 vs 1140 Other: 322 vs 312
Tavazzi 2008 (GISSI HF) ²⁶	543 (23.8) vs 489 (21.4)	NR
Budinski 2009 ⁴²	338 (54.9) vs 105 (51)	NR
Ose 2009 ⁴⁶	391 (62) vs 111 (51.2)	NR
Athyros 2010 (GREACE) ³¹	182 (20.7) vs 162 (18.4)	NR
Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	53 (39.5) vs 50 (37.0)	White: 131 (97.8) vs 133 (98.5)
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	200/1026 (19.5%)	NR
Collier 2011 (ASCOT-LLA) ³⁷	409 (18.7) vs 464 (20.6)	White 2105 (96.2) vs 2167 (96.1) White 2784 (93.5) vs 2696 (93.6)
Nozue 2012 (TRUTH) ⁴⁴	570 (19.13) vs 499 (17.32)	NR
Chen 2013 ²⁴	20 (16.8)	White: 245 (82.5) vs 321 (73.6) Hispanic: 37 (12.5) vs 90 (20.6) Black: 10 (3.4) vs 7 (1.6) Other: 5 (1.7) vs 18 (4.1) White: 242 (81.2) vs 314 (71.5) vs 323 (73.9) vs 316 (73) Hispanic: 37 (12.4) vs 91 (20.7) vs 86 (19.7) vs 83 (19.2)
Kurogi 2013 (COMPACT-CAD) ⁴³	165 (55.6) vs 237 (54.4)	White: 245 (82.5) vs 321 (73.6) Hispanic: 37 (12.5) vs 90 (20.6) Black: 10 (3.4) vs 7 (1.6) Other: 5 (1.7) vs 18 (4.1) White: 242 (81.2) vs 314 (71.5) vs 323 (73.9) vs 316 (73) Hispanic: 37 (12.4) vs 91 (20.7) vs 86 (19.7) vs 83 (19.2)
Shen 2013 (NCT0097786; NAVIGATOR) ³⁸	12 (18.5) vs 12 (18.7)	Black: 11 (3.7) vs 8 (1.8) vs 7 (1.6) vs 8 (1.8)
NK-104-4-01CH ⁴⁷	690 (51) vs 2684 (56)	Others: 8 (2.7) vs 26 (5.9) vs 21 (4.8) vs 26 (6.0)
Ong 2014 (TNT) ³⁶	NR	NR
INTREPID ⁴¹	961 (19) vs 941 (19) 20 (16.3) vs 15 (12.1)	Black: 28 (2.1) vs 134 (2.8)

NR = not reported; RCT = randomised controlled trial; IQR = interquartile range; SE = standard error; SD = standard deviation; ERN/LRPT = Extended-release niacin/laropiprant; IFG = impaired fasting glucose.

Table 2. Characteristics of included studies

Study name	Study design	Study duration	Study groups
PMSGCRP 1993 ³⁷ 4S 1994 ²⁸	RCT, double-blind RCT, double-blind	3.1 years 5.4 years	Pravastatin 20 mg vs placebo Simvastatin vs Placebo
Downs 1998 (AFCAPS/TEXCAPS) ³³ GISSI PREV 2000 ¹⁹	RCT, double-blind RCT, open-label	5.2 years 3.2 years	Lovastatin vs Placebo Pravastatin vs Usual care
Freeman 2001 (WOSCOPS) ¹² ALLHAT 2002 ²⁹	RCT, double-blind RCT, open-label	4.8 years 4.8 years	Pravastatin 40 mg vs Placebo Pravastatin vs Usual care
Saito 2002 ⁴⁵ Shepherd 2002 (PROSPER) ¹¹	RCT, double-blind RCT, double-blind	12 weeks 3.2 years	Pitavastatin 2 mg vs Pravastatin 10 mg Pravastatin vs Placebo
Collins 2003 (HPS) ²⁵ Keech 2003 (LIPID) ¹⁸	RCT, double-blind RCT, double-blind	5 years 6.1 years	Simvastatin 40 mg vs Placebo Pravastatin vs placebo
Pedersen 2005 (IDEAL) ⁴⁰	RCT, Open label, blinded end-point	4.8 years	Atorvastatin 80 mg vs Simvastatin 20e-40 mg
Amarenco 2006 (SPARCL) ³⁹ Nakamura 2006 (MEGA) ³⁵	RCT, double-blind RCT, open-label	4.9 years 5.3 years	Atorvastatin 80 mg vs Placebo Diet + pravastatin vs Diet
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	RCT, double-blind	Median 32.8 months (2.7 years)	Rosuvastatin vs placebo
Ridker 2008 (Jupiter; NCT00239681) ¹⁰ Tavazzi 2008 (GISSI HF) ²⁶	RCT, double-blind RCT, double-blind	60 months (5 years) 3.9 years	Rosuvastatin vs Placebo Rosuvastatin vs Placebo
Budinski 2009 ⁴² Ose 2009 ⁴⁶	RCT, double-blind RCT, double-blind	12 weeks 12 weeks	Pitavastatin 2-4 mg vs Atorvastatin 10-20 mg Pitavastatin 2-4 mg vs Simvastatin 20-40 mg
Athyros 2010 (GREACE) ³¹ Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	RCT, open label, survival study RCT, double-blind	3 years 3.5 years	Statin vs no statin Rosuvastatin vs placebo
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰ Collier 2011 (ASCOT-LLA) ³⁷	RCT, double-blind RCT, double-blind	Mean: 6.7 (SD 1.5) person-years Median 3.3 years	Simvastatin 80 mg vs 20 mg Atorvastatin vs placebo (≥65 years) Atorvastatin vs placebo (<65 years)
Nozue 2012 (TRUTH) ⁴⁴ Chen 2013 ²⁴	RCT, open label RCT, double-blind	32 weeks 3.5 months	Pitavastatin 4 mg vs Pravastatin 20 mg ERN/LRPT + Simvastatin 20 vs ERN/LRPT + Simvastatin 40
Kurogi 2013 (COMPACT-CAD) ⁴³ Shen 2013 (NCT00097786; NAVIGATOR) ³⁸	RCT, open label Re-analysis- NAVIGATOR trial	2.3 years Median 5.0 years	Atorvastatin 10 vs 20 vs 40 vs 80 Pitavastatin 2-4 mg vs Atorvastatin 10-20 mg Statins vs No Statins
NK-104-4-01CH ⁴⁷ Ong 2014 (TNT) ³⁶ INTREPID ⁴¹	RCT, open label RCT, double-blind RCT, double-blind	12 weeks Median 4.9 years 12/52 weeks	Pitavastatin 4 mg vs Atorvastatin 20 mg Atorvastatin 10 mg vs 80 mg Pitavastatin 4 mg vs Pravastatin 40 mg

NR = not reported; RCT = randomised controlled trial; MI = myocardial infarction. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; HTN = hypertension. AF = atrial fibrillation; ACEi = angiotensinogen converting enzyme inhibitor; ARB = angiotensin receptor blocker; PTCA = percutaneous transluminal coronary angioplasty; OHA = oral hypoglycaemic agents; IQR = interquartile range; SE = standard error; SD = standard deviation; CHF = congestive heart failure; HR = hazard ratio; LVH = left ventricular hypertrophy; TIA = transient ischaemic attack; ECG = electrocardiogram; PVD = peripheral vascular disease; ERN/LRPT = extended-release niacin/laropiprant; IFG = impaired fasting glucose; PAD = peripheral artery disease; FBG = fasting blood glucose; CCB = calcium channel blocker; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; HIV = human immunodeficiency virus; CAD = coronary artery disease.

Table 2. Characteristics of included studies

Study name	No of patients	History of previous events; n (%)
PMSGCRP 1993 ³⁷	530 vs 532	MI: 172 (32) vs 194 (36)
4S 1994 ²⁸	2221 vs 2223	Previous CABG or angioplasty: 189 (9) vs 151 (7)
Downs 1998 (AFCAPS/TEXCAPS) ³³	3304 vs 3301	Family history of premature CHD: 497 (15) vs 538 (16)
GISSI PREV 2000 ¹⁹	2138 vs 2133	NR
Freeman 2001 (WOSCOPS) ¹²	3302 vs 3293	NR
ALLHAT 2002 ²⁹	5170 vs 5185	CHD: 695 (13.4) vs 780 (15.0)
Saito 2002 ⁴⁵	240	NR
Shepherd 2002 (PROSPER) ¹¹	2891 vs 2913	Angina: 806 (27.9) vs 753 (25.8)
Collins 2003 (HPS) ²⁵	10 269 vs 10 267	Claudication: 198 (6.8) vs 192 (6.6) MI: 377 (13) vs 399 (13.7)
Keech 2003 (LIPID) ¹⁸	4512 vs 4502	Stroke or TIA: 328 (11.3) vs 321 (11) PAD surgery: 67 (2.3) vs 56 (1.9)
Pedersen 2005 (IDEAL) ⁴⁰	4439 vs 4449	Prior MI: 87% vs 22% Other CHD: 85% vs 18% No CHD: 83% vs 11%
Amarenco 2006 (SPARCL) ³⁹	2365 vs 2366	MI: 2879 (64) vs 2875 (64) Unstable angina: 1633 (36) vs 1627 (36)
Nakamura 2006 (MEGA) ³⁵	3866 vs 3966	Stroke: 171 (4) vs 198 (4) PTCA only: 502 (11) vs 486 (11)
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	2514 vs 2497	CABG only: 1217 (27) vs 1219 (27) Both PTCA and CABG: 135 (3) vs 133 (3)
Ridker 2008 (Jupiter; NCT00239681) ¹⁰	8901 vs 8901	MI: 1231 (28.1) vs 1262 (28) CABG: 732 (16.5) vs 747 (16.8)
Tavazzi 2008 (GISSI HF) ²⁶	2285 vs 2289	Stroke: 1655 (70) vs 1613 (68.2) TIA: 708 (29.9) vs 752 (31.8)
Budinski 2009 ⁴²	616 vs 205	NR
Ose 2009 ⁴⁶	631 vs 217	MI: 1510 (60) vs 1494 (60) Past or current angina pectoris: 1831 (73) vs 1807 (72)
Athyros 2010 (GREACE) ³¹	880 vs 720	CABG or PCI: 660 (26) vs 638 (26) Stroke: 315 (13) vs 309 (12)
Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	134 vs 135	MI: 727 (31.8) vs 774 (33.8) Stroke: 99 (4.3) vs 109 (4.8)
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	6031 vs 6033	CABG: 296 (13) vs 319 (13.9) PCI: 185 (8.1) vs 192 (8.4)
Collier 2011 (ASCOT-LLA) ³⁷	2189 vs 2256	ICD: 146 (6.4) vs 155 (6.8) AF: 440 (19.3) vs 477 (20.8)
Nozue 2012 (TRUTH) ⁴⁴	2979 vs 2881	NR
Chen 2013 ²⁴	58 vs 61	NR
Kurogi 2013 (COMPACT-CAD) ⁴³	297 vs 436	MI alone: 656/2955 vs 669/2890
Shen 2013 (NCT0097786; NAVIGATOR) ³⁸	298 vs 439	+Other CHD: 631/2484 vs 658/2557+Other vascular: 164/524 vs 205/538
NK-104-4-01CH ⁴⁷	vs 437 vs 433	+DM: 225/633 vs 245/634
Ong 2014 (TNT) ³⁶	65 vs 64	Previous stroke or TIA: 285 (13) vs 319 (14.1)
INTREPID ⁴¹	476	Previous stroke or TIA: 200 (6.7) vs 197 (6.8)
	5006 vs 4995	CAD: 119 (100) Multivessel PCI: 8 (6.7)
	123 vs 124	NR
		PCI: 55 (84.6) vs 55 (86.0) MI: 33 (50.8) vs 32 (50.0) CAD: 12 (18.5) vs 13 (20.3)
		CABG: 41 (3) vs 67 (1.4) Angina: 175 (13) vs 508 (10.6)
		NR
		MI: 2888 (57.7) vs 2945 (59) Angina: 4067 (81.2) vs 4084 (81.8)
		Cerebrovascular accident: 263 (5.3) vs 255 (5.1) PAD: 570 (11.4) vs 603 (12.1)
		CHD: 404 (8.1) vs 377 (7.6) Arrhythmia: 927 (18.5) vs 907 (18.2)
		Angioplasty: 2719 (54.3) vs 2688 (53.8) CABG: 2338 (46.7) vs 2317 (46.4)
		NR

NR = not reported; RCT = randomised controlled trial; MI = myocardial infarction. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; HTN = hypertension. AF = atrial fibrillation; ACEi = angiotensinogen converting enzyme inhibitor; ARB = angiotensin receptor blocker; PTCA = percutaneous transluminal coronary angioplasty; OHA = oral hypoglycaemic agents; IQR = interquartile range; SE = standard error; SD = standard deviation; CHF = congestive heart failure. HR = hazard ratio; LVH = left ventricular hypertrophy; TIA = transient ischaemic attack; ECG = electrocardiogram; PVD = peripheral vascular disease; ERN/LRPIT = extended-release niacin/laropiprant; IFG = impaired fasting glucose; PAD = peripheral artery disease; FBG = fasting blood glucose; CCB = calcium channel blocker; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; HIV = human immunodeficiency virus; CAD = coronary artery disease.

Table 2. Characteristics of included studies

Study name	Co-morbidities; n (%)
PMSGCRP 1993 ³⁷	HTN: 251 (47) vs 253 (48) Angina: 198 (37) vs 231 (43)
4S 1994 ²⁸	HTN: 570 (26) vs 584 (26) Claudication: 130 (6) vs 123 (6) DM: 105 (5) vs 96 (4)
Downs 1998 (AFCAPS/TEXCAPS) ³³	HTN: 719 (22) vs 729 (22) Non-insulin treated DM: 84 (3.0) vs 71 (2.0) Non-insulin-treated DM or FBG \geq 126 mg/dl: 126 (3.8) vs 113 (3.4)
GISSI PREV 2000 ¹⁹	DM: 13.6% HTN: 36.5%
Freeman 2001 (WOSCOPS) ¹²	Angina: 164 (5) vs 174 (5) Intermittent claudication: 97 (3) vs 96 (3) DM: 41 (1) vs 35 (1)
ALLHAT 2002 ²⁹	HTN: 531 (16) vs 506 (15) Minor ECG abnormality: 275 (8) vs 259 (8)
Saito 2002 ⁴⁵	DM: 1855 (35.9) vs 1783 (34.4)
Shepherd 2002 (PROSPER) ¹¹	NR
Collins 2003 (HPS) ²⁵	DM: 303 (10.5) vs 320 (11) HTN: 1799 (62.2) vs 1793 (61.6) Vascular disease: 1306 (45.2) vs 1259 (43.2)
Keech 2003 (LIPID) ¹⁸	NR
Pedersen 2005 (IDEAL) ⁴⁰	Systemic HTN: 1867 (41) vs 1891 (42) DM: 396 (9) vs 386 (9) Obesity: 823 (18) vs 788 (18)
Amarengo 2006 (SPARCL) ³⁹	DM: 532 (12.0) vs 537 (12.1) HTN: 1461 (32.9) vs 1469 (33.0) CVD: 353 (8.0) vs 376 (8.5) PVD: 182 (4.1) vs 195 (4.4) CHF: 293 (6.6) vs 244 (5.5) AF: 347 (7.8) vs 336 (7.6)
Nakamura 2006 (MEGA) ³⁵	HTN: 1476 (62.4) vs 1452 (61.4) DM: 395 (16.7) vs 399 (16.9)
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	HTN: 1613 (42) vs 1664 (42) DM: 804 (21) vs 828 (21)
Ridker 2008 (Jupiter; NCT00239681) ¹⁰	HTN: 1594 (63) vs 1581 (63) DM: 743 (30) vs 734 (29) Current AF or flutter: 609 (24) vs 585 (23)
Tavazzi 2008 (GISSI HF) ²⁶	Metabolic syndrome: 3652 (41) vs 3723 (41.8)
Budinski 2009 ⁴²	HTN: 1260 (55.1) vs 1224 (53.5) DM: 625 (27.4) vs 571 (25) PVD: 184 (8.1) vs 160 (7)
Ose 2009 ⁴⁶	COPD: 538 (23.5) vs 522 (22.8) Neoplasia: 76 (3.3) vs 91 (4.0)
Athyros 2010 (GREACE) ³¹	NR
Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	NR
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	DM: 173 (19.7%) vs 140 (19.4%) Metabolic syndrome: 365 (41.4%) vs 347 (48.2%)
Collier 2011 (ASCOT-LLA) ³⁷	NR
Nozue 2012 (TRUTH) ⁴⁴	DM: 570 (26) vs 620 (27.5) LVH: 570 (26) vs 620 (27.5) ECG abnormalities : 383 (17.5) vs 378 (16.8)
Chen 2013 ²⁴	PVD: 155 (7.1) vs 142 (6.3)
Kurogi 2013 (COMPACT-CAD) ⁴³	DM: 688 (23.1) vs 654 (22.7) LVH: 404 (13.6) vs 415 (14.4) ECG abnormalities : 358 (12.0) vs 351 (12.2)
Shen 2013 (NCT00097786; NAVIGATOR) ³⁸	PVD: 106 (3.6) vs 111 (3.9)
NK-104-4.01CH ⁴⁷	DM: 50 (42) HTN: 75 (63.1)
Ong 2014 (TNT) ³⁶	DM: 9 (3.0) vs 20 (4.6) Metabolic syndrome: 185 (62.3) vs 296 (67.9)
INTREPID ⁴¹	DM: 11 (3.7) vs 20 (4.6) vs 27 (5.9) vs 27 (6.2) Metabolic syndrome: 194 (65.1) vs 301 (68.6) vs 295 (67.5) vs 315 (72.7)
	DM: 27 (41.5) vs 25 (39.1) HTN: 54 (83.1) vs 53 (82.8)
	HTN: 1036 (76.6) vs 4002 (83.5) CHF: 38 (2.8) vs 172 (3.6)
	NR
	HTN: 2721 (54.4) vs 2692 (53.9) DM: 753 (15) vs 748 (15)
	HIV infection

NR = not reported; RCT = randomised controlled trial; MI = myocardial infarction. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; HTN = hypertension. AF = atrial fibrillation; ACEi = angiotensinogen converting enzyme inhibitor; ARB = angiotensin receptor blocker; PTCA = percutaneous transluminal coronary angioplasty; OHA = oral hypoglycaemic agents; IQR = interquartile range; SE = standard error; SD = standard deviation; CHF = congestive heart failure. HR = hazard ratio; LVH = left ventricular hypertrophy; TIA = transient ischaemic attack; ECG = electrocardiogram; PVD = peripheral vascular disease; ERN/LRPT = extended-release niacin/farapitant; IFG = impaired fasting glucose; PAD = peripheral artery disease; FBG = fasting blood glucose; CCB = calcium channel blocker; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; HIV = human immunodeficiency virus; CAD = coronary artery disease.

Table 2. Characteristics of included studies

Study name	Co-mediations; n (%)
PMSCGRP 1993 ³⁷ 4S 1994 ²⁸	NR Aspirin: 822 (37) vs 815 (37) β -blockers: 1258 (57) vs 1266 (57) CCBs: 712 (32) vs 668 (30) Isosorbide mono/dinitrate: 684 (31) vs 727 (33) Thiazides: 151 (7) vs 138 (6) Warfarin: 29 (1) vs 51 (2) Fish oil: 283 (13) vs 293 (13)
Downs 1998 (AFCAPS/TEXCAPS) ³³	Antihypertensives: 661 (20) vs 695 (21.1) ACEi: 244 (7.4) vs 257 (7.8) α -blockers: 68 (2.1) vs 67 (2.0) β -blockers: 141 (4.3) vs 156 (4.7) CCBs: 171 (5.2) vs 170 (5.1) Diuretics: 203 (6.1) vs 203 (6.1) Oestrogen \pm progestins: 155 (31.1) vs 137 (27.5) NSAIDs: 494 (15) vs 445 (13.5) OHDs: 41 (1.2) vs 43 (1.3) Thyroid replacement hormone: 132 (4) vs 107 (3.2) Aspirin: 571 (17.3) vs 561 (17) Antiplatelet agents > 90% β -blockers 42.7% ACEi 40.2%
GISSI PREV 2000 ¹⁹ Freeman 2001 (WOSCOPS) ¹² ALLHAT 2002 ²⁹ Saito 2002 ⁴⁵ Shepherd 2002 (PROSPER) ¹¹ Collins 2003 (HPS) ²⁵ Keech 2003 (LIPID) ¹⁸ Pedersen 2005 (IDEAL) ⁴⁰ Amarenco 2006 (SPARCL) ³⁹ Nakamura 2006 (MEGA) ³⁵ Kjekshus 2007 (NCT00206310; CORONA) ³⁴	NR Women taking oestrogen: 390 (15.5) vs 399 (15.7) Aspirin: 1566 (30.3) vs 1637 (31.6) Antihypertensives: 4641 (89.8) vs 4663 (89.9) NR NR NR Aspirin: 3726 (83) vs 3689 (82) β -blocker: 2090 (46) vs 2152 (48) Calcium antagonist: 1563 (35) vs 1610 (36) ACEi: 720 (16) vs 719 (16) Nitrate: 1599 (35) vs 1610 (36) Diuretic: 727 (16) vs 761 (17) Insulin: 60 (1) vs 49 (1) OHD: 236 (5) vs 262 (6) Aspirin: 3494 (78.7) vs 3536 (79.5) Warfarin or dicoumarol: 558 (12.6) vs 559 (12.6) β -blockers: 3377 (76.1) vs 3281 (73.7) CCBs: 882 (19.9) vs 840 (18.9) ACEi: 1296 (29.2) vs 1367 (30.7) ARBs: 263 (5.9) vs 270 (6.1) Antiplatelet therapy: 2067 (87.4) vs 2063 (87.2) ACEi: 683 (28.9) vs 667 (28.2) CCBs: 350 (14.8) vs 359 (15.2) β -blocker: 414 (17.5) vs 422 (17.8) ARBs: 110 (4.7) vs 102 (4.3) Vitamin K antagonist: 139 (5.9) vs 154 (6.5) Antihypertensives: 1491 (39) vs 1549 (39) CCBs: 1017 (26) vs 1048 (26) ACEi/ARB: 473 (12) vs 512 (13) β -blockers: 318 (8) vs 329 (8) Diuretics: 111 (3) vs 128 (3) Aspirin: 36 (1) vs 42 (1) Loop or thiazide diuretic: 2231 (89) vs 2185 (88) Aldosterone antagonist: 986 (39) vs 979 (39) ACEi or ARB: 2292 (91) vs 2307 (92) β -blocker: 1887 (75) vs 1879 (75) Digitalis glycoside: 845 (34) vs 803 (32) Antiarrhythmic therapy: 306 (12) vs 289 (12) Antiplatelet or anticoagulant therapy: 2273 (90) vs 2251 (90) Aspirin: 1481 (16.6) vs 1477 (16.6) Previous medical treatment was given
Ridker 2008 (Jupiter; NCT00239681) ¹⁰ Tavazzi 2008 (GISSI HF) ²⁶ Budinski 2009 ⁴² Ose 2009 ⁴⁶ Athrys 2010 (GREACE) ³¹ Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³² Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰ Collier 2011 (ASCOT-LLA) ³⁷ Nozue 2012 (TRUTH) ⁴⁴ Chen 2013 ²⁴ Kurogi 2013 (COMPACT-CAD) ⁴³ Shen 2013 (NCT00097786; NAVIGATOR) ³⁸ NK-104-4-01CH ⁴⁷ Ong 2014 (TNT) ³⁶ INTREPID ⁴¹	NR NR NR NR Aspirin and other antiplatelet agents, β -blockers, ACE inhibitors or ARB, Nitrates, CCBs, Diuretics NR NR NR Aspirin: 117 (98.3) Thienopyridines: 118 (99.2) ACEi: 61 (51.3) β -blocker: 13 (10.9) CCBs: 60 (50.4) Statins: 25 (38.5) vs 24 (37.5) CCBs: 31 (47.7) vs 33 (51.6) β -blocker: 22 (33.8) vs 20 (31.3) ACEi: 22 (33.8) vs 22 (34.4) ARBs: 23 (35.4) vs 23 (35.9) Insulin: 20 (30.8) vs 5 (7.8) Sulfonylurea: 9 (13.8%) vs 7 (10.9) α -glucosidase inhibitor: 6 (9.2) vs 5 (7.8) Antiplatelet agents: 65 (100) vs 63 (98.4) Nitrate: 15 (23.1) vs 14 (21.9) NR NR NR NR

NR = not reported; RCT = randomised controlled trial; MI = myocardial infarction. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; HTN = hypertension. AF = atrial fibrillation; ACEi = angiotensinogen converting enzyme inhibitor; ARB = angiotensin receptor blocker; PTCA = percutaneous transluminal coronary angioplasty; OHA = oral hypoglycaemic agents; IQR = interquartile range; SE = standard error; SD = standard deviation; CHF = congestive heart failure. HR = hazard ratio; LVH = left ventricular hypertrophy; TIA = transient ischaemic attack; ECG = electrocardiogram; PVD = peripheral vascular disease; ERN/LRPT = extended-release niacin/laropiprant; IFG = impaired fasting glucose; PAD = peripheral artery disease; FBG = fasting blood glucose; CCB = calcium channel blocker; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; HIV = human immunodeficiency virus; CAD = coronary artery disease.

Table 2. Characteristics of included studies

Study name	N developing diabetes/N non-diabetic patients
PMSGCRP 1993 ³⁷	1/530 vs 0/532
4S 1994 ²⁸	198/2116 vs 193/2126
Downs 1998 (AFCAPS/TEXCAPS) ³³	72/3094 vs 74/3117
GISSI PREV 2000 ¹⁹	96/1743 vs 105/1717
Freeman 2001 (WOSCOPS) ¹²	75/2999 vs 93/2975
ALLHAT 2002 ²⁹	238/3017 vs 212/3070
Saito 2002 ⁴⁵	1/84 vs 1/81
Shepherd 2002 (PROSPER) ¹¹	165/2510 vs 127/2513
Collins 2003 (HPS) ²⁵	335/7291 vs 293/7282
Keech 2003 (LIPID) ¹⁸	126/3150 vs 138/3067
Pedersen 2005 (IDEAL) ⁴⁰	240/3907 vs 209/3912
Amarenco 2006 (SPARCL) ³⁹	166/1908 vs 115/1916
Nakamura 2006 (MEGA) ³⁵	172/3013 vs 164/3073
Kjekshus 2007 (NCT00206310; CORONA) ³⁴	100/1771 vs 88/1763
Ridker 2008 (Jupiter; NCT00239681) ¹⁰	270/8901 vs 216/8901
Tavazzi 2008 (GISSI HF) ²⁶	225/1660 vs 215/1718
Budinski 2009 ⁴²	1/576 vs 2/179
Ose 2009 ⁴⁶	1/592 vs 0/202
Athyros 2010 (GREACE) ³¹	29/707 vs 25/580
Chan 2010 (ASTRONOMER, ISRCTN 32424163) ³²	1/134 vs 0/135
Armitage 2010 (ISRCTN74348595, SEARCH trial) ³⁰	625/6031 vs 587/6033
Collier 2011 (ASCOT-LLA) ³⁷	61/2189 vs 70/2256
Nozue 2012 (TRUTH) ⁴⁴	140/2979 vs 109/2881
Chen 2013 ²⁴	2/38 vs 2/31
	New diagnosis of IFG: 1/605 (0.2) New onset diabetes: 6/703 (0.9)
	New diagnosis of IFG: 1/1343 (0.1) New onset diabetes: 3/1523 (0.2)
Kurogi 2013 (COMPACT-CAD) ⁴³	1/36 vs 3/35
Shen 2013 (NCT00097786; NAVIGATOR) ³⁸	Progression to diabetes; unadjusted HR 1.30 (95%CI 1.14 to 1.48), baseline adjusted HR 1.30 (95%CI 1.13 to 1.49)
NK-104-4.01CH ⁴⁷	9/280 vs 2/142
Ong 2014 (TNT) ³⁶	308/4253 vs 351/4274
INTREPID ⁴¹	0/123 vs 4/124

NR = not reported; RCT = randomised controlled trial; MI = myocardial infarction. CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; HTN = hypertension. AF = atrial fibrillation; ACEi = angiotensinogen converting enzyme inhibitor; ARB = angiotensin receptor blocker; PTCA = percutaneous transluminal coronary angioplasty; OHA = oral hypoglycaemic agents; IQR = interquartile range; SE = standard error; SD = standard deviation; CHF = congestive heart failure. HR = hazard ratio; LVH = left ventricular hypertrophy; TIA = transient ischaemic attack; ECG = electrocardiogram; PVD = peripheral vascular disease; ERN/LRPT = extended-release niacin/laropiprant; IFG = impaired fasting glucose; PAD = peripheral artery disease; FBG = fasting blood glucose; CCB = calcium channel blocker; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; HIV = human immunodeficiency virus; CAD = coronary artery disease.

In the comparison of intensive versus moderate statin therapy, we found that intensive treatment significantly increased the risk of diabetes in the pooled estimate (pooled OR 1.12; 95%CI 1.01–1.24; I^2 13%; $p=0.04$; 7 RCTs) under the random-effects model. (Figure 3a)

Four of the seven pitavastatin trials,^{42,43,46,47} which compared pitavastatin with other equivalent potency statins showed reduction in odds of diabetes in the pitavastatin arm; however, this difference was not statistically significant (pooled OR 0.69; 95%CI 0.18–2.65; I^2 31%; $p=0.59$; 4 RCTs) in the random-effects model. (Figure 3b)

Meta-regression. We performed the meta-regression analysis for the main pairwise meta-analysis to explore the reasons for low-moderate heterogeneity (I^2 : 36%, Figure 2). We entered the covariates such as age, follow-up duration, BMI and LDL levels in the meta-regression model, which are reported to be strongly related to the likelihood of developing diabetes in the literature. All the variables were entered, at a time, in the analysis to perform a joint test for all covariates. None of the covariates was significantly associated with the difference between the studies for development of diabetes (p -value

STATINS AND RISK OF DIABETES




Figure 2. Forest plot for pairwise meta-analysis

for the joint test 0.25) [Appendix Table S1]. However, around 6% of the heterogeneity was explained by these covariates, resulting in around 29% residual heterogeneity in the adjusted model.

Network meta-analysis (combination of direct and indirect comparisons). We included 27 studies in the NMA; two studies^{31,38} compared any statin versus without statin and were excluded from the analysis (Figure 1). Pravastatin versus placebo (seven studies) was the most prevalent comparison followed by rosuvastatin versus placebo (four studies) and atorvastatin versus pitavastatin (three

studies). Figure 4 shows network of the treatments for the development of diabetes. Each line links the treatments directly compared in the trial. The thickness of the edge is proportional to the mean control group risk for the comparisons included in the network; the width of the circle is proportional to the number of studies involving the specific treatment. No visible difference in the thickness of the edges supports the fulfilment of transitivity assumption of the network. The colour of the edge depicts RoB for that comparison; red for 'high', green for 'low' and yellow for 'unclear' RoB. From the figure, it can be seen that placebo was the most commonly used comparator.




Figure 3. (a) Forest plot: Intensive versus moderate statin treatment; (b) Forest plot: equal potency statin treatment




Figure 4. Network plot of available direct comparisons. Thickness of the edge is proportional to the mean control group risk for the comparisons included in the network; the width of the circle (node) is proportional to the number of studies involving the specific treatment; colour of the edge indicate risk of bias in a comparison (red = high, yellow = moderate and green = low)

There was evidence of statistical and clinical inconsistency in the two triangular loops atorvastatin–placebo–simvastatin and atorvastatin–atorvastatin 80mg–simvastatin with the ratio of odds ratio ROR 4.4; 95%CI 1.08–18.04 and ROR 4.41; 95%CI 1.08–18.09, respectively. Other triangular loops; atorvastatin–pitavastatin–simvastatin, atorvastatin–atorvastatin 80mg–placebo and atorvastatin 80mg–placebo–simvastatin and quadrilateral loops;

pitavastatin–placebo–pravastatin–simvastatin and atorvastatin–pitavastatin–placebo–pravastatin in the network did not show significant inconsistency (Figure 5).

Summary odds ratios with their 95% CIs and predictive intervals (PrIs) is shown as forest plot or interval plot for each statin versus placebo and statin versus active comparator in Figure 6. Rosuvastatin and atorvastatin 80 mg increased the risk of developing diabetes significantly compared with placebo. Atorvastatin 80 mg was ranked highest for increasing the risk of diabetes with OR 1.34 (95%CI 1.14–1.57) followed by OR: 1.17 (95%CI 1.02–1.35) for rosuvastatin, 1.21 (95%CI 0.99–1.49) for simvastatin 80 mg, 1.13 (95%CI 0.99–1.29) for simvastatin, 1.13 (95%CI 0.94–1.34) for atorvastatin, 1.04 (95%CI 0.93–1.16) for pravastatin, 0.98 (95%CI 0.69–1.38) for lovastatin, and 0.74 (95%CI 0.31–1.77) for pitavastatin.

In the NMA, atorvastatin 80 mg increased the odds of developing diabetes even compared with pravastatin (OR: 1.29; 95%CI: 1.06–1.56), simvastatin (OR: 1.18; 95%CI 1.01–1.39), and atorvastatin 10 mg ([OR: 1.19; 95%CI: 1.01–1.40] Figure 6).

Contribution plot for all the possible direct and indirect comparisons is presented in Figure S3. From the figure, it can be seen that simvastatin versus placebo is the most influential comparison with the contribution of 16.2% followed by pravastatin versus placebo with 13% for the entire network. Atorvastatin 80 mg versus simvastatin is the least influential comparison in the entire network with weight of just 0.1% and benefits most from the network as little direct evidence

STATINS AND RISK OF DIABETES




Figure 5. Inconsistency plot for evaluating consistency within first order closed loops. Risk of odds ratio between direct and indirect evidence is reported on X-axis. ATO = atorvastatin; PLA = placebo; SIM = simvastatin; PRA = pravastatin; PIT = pitavastatin; ATO-80 = atorvastatin 80 mg; ROR = ratio of odds ratio; CI = confidence interval

exists for it. It is interesting to note that, in the pairwise estimate, simvastatin significantly increased the odds of developing diabetes compared with atorvastatin ([OR 4.36; 95%CI 1.09–17.49] Figure 2) and seemed to have limited power, but after obtaining the benefit from network, this comparison reduced to non-significant ([OR 1.00; 95%CI 0.83–1.22] Figure 6).

Publication bias. Figure S4 shows the ‘comparison-adjusted’ funnel plot for our network. In this plot, the horizontal axis presents the difference between the study-specific effect sizes from the corresponding comparison-specific summary effect. In the absence of small study effects, the comparison-adjusted funnel plot should be symmetric around the zero line. In our analysis, although small study effects were seen for some of the studies, these comparison-specific studies were symmetrically distributed around the line of no difference.

Hydrophilic versus lipophilic statins. Subgroup analysis including 19 studies^{3,10,12,18,19,25–29,32–35,37,39,41,44,45} that compared hydrophilic or lipophilic

statins with placebo or to each other was performed. In the subgroup analysis, lipophilic statins increased the risk of developing diabetes significantly compared with placebo (OR: 1.14; 95%CI: 1.02–1.28) in the mixed estimate. However, for the head-to-head comparison in the mixed estimate, lipophilic statins did not increase the risk significantly when compared with hydrophilic statins (OR: 1.05; 95%CI: 0.9–1.23). [Figure S5]

DISCUSSION

Our study was aimed to use NMA to generate evidence on whether statin use predisposed patients to a risk of developing diabetes. Our analysis was limited to the onset of diabetes and did not take into account the exacerbation of diabetes-related complications in pre-existing diabetes patients. We included 29 studies for the pairwise meta-analysis and 27 articles for the NMA. Our pairwise meta-analysis demonstrated an increasing risk to diabetes at 12%, with low-moderate heterogeneity. The low-moderate heterogeneity suggests that most variation was attributable to chance alone. Rosuvastatin was the only statin associated with statistically significant higher odds of increasing diabetes to 18%.




Figure 6. Forest plot (Interval plot): each statin versus placebo and statin versus active comparator. Black lines around the diamond for each comparison indicate the confidence interval while the red line indicates the predictive interval. This plot depicts estimated summary effects along with their confidence intervals and their corresponding PrI for all comparisons and summarizes in one plot the relative mean effects, predictions and the impact of heterogeneity on each comparison. The plot indicates that for one of these comparisons (ROS vs PLA), the PrI is wide enough compared with the CI to suggest that in a future study, the rosuvastatin can have lesser risk of developing diabetes than placebo, although the lower CI limit does not cross the line of no effect. CI = confidence interval; PrI = predictive interval; ROS = rosuvastatin; PLA = placebo; PRA = pravastatin; ATO = atorvastatin; SIM = simvastatin; A80 = atorvastatin 80 mg; S80 = simvastatin 80 mg; LOV = lovastatin; PIT = pitavastatin

Two of the earlier systematic reviews and meta-analyses^{13,14} had already concluded that statin significantly increased the risk of diabetes by about 9%. Our pairwise meta-analysis also found a similar risk at 13% without significant heterogeneity. Sattar *et al.*¹³ included 13 RCTs with 91 140 participants, of whom 4278 developed diabetes during a mean of 4 years (2226 assigned statins and 2052 assigned control treatment). Mills *et al.*¹⁴ evaluated the incidence of diabetes available from 17 RCTs enrolling 111 003 individuals, 2215 assigned to statin and 2048 to control developed diabetes. Sattar *et al.*¹³ reported that among statins, rosuvastatin was the only statin that was associated with statistically significantly higher odds of diabetes in three trials. We also found the similar results for rosuvastatin in the pooled analysis of the four trials that we included. Additionally, Sattar *et al.*¹³ reported that hydrophilic and lipophilic statins were associated with similar risk for developing

diabetes compared with placebo. We found lipophilic statins to be significantly associated with 14% higher risk of diabetes compared with placebo. This can be explained by the fact that lipophilic statins have higher half-life and are excreted slowly and therefore, remain in the body longer. Sattar *et al.*¹³ could not probably detect this difference because of the limited number of studies included, thereby providing less power to the comparison. However, in the head-to-head comparison in the network meta-analysis, there was no significant difference between hydrophilic and lipophilic statins for the likelihood of developing diabetes.

Naci *et al.*¹⁶ conducted a comprehensive NMA involving 246 955 participants from 135 RCTs to evaluate the comparative tolerability and harms of individual statins. This review found similar results as our study for the pairwise meta-analysis; however, in the NMA, there were no statistically detectable differences between individual statins for the

incidence of diabetes mellitus. Navarese *et al.*¹⁷ investigated the impact of different types and doses of statins on new-onset diabetes employing the NMA methodology. This study included similar subset of studies as Naci *et al.*¹⁶ for the diabetes outcomes and also found that none of the individual statins increased the odds of developing diabetes. Their study did not find any significant association between higher-dose statins like atorvastatin 80 mg and diabetes. Conversely, from the NMA, we found that atorvastatin 80 mg and rosuvastatin significantly increased the risk of developing diabetes by 34% and 17%, respectively. We also found that higher-dose atorvastatin even increased the risk of diabetes compared with other statins like pravastatin, simvastatin and low-dose atorvastatin. Furthermore, simvastatin 80 mg versus placebo has an effect size marginally higher than rosuvastatin vs placebo (1.21 vs 1.17) and the lower CIs of statistically insignificant simvastatin 80 mg and of significant rosuvastatin are close to 1 (0.99 vs 1.02). The difference in the results between the previous NMAs and our NMA could be attributed to two reasons. Firstly, to explore the association between statins and diabetes, Naci *et al.*¹⁶ and Navarese *et al.*¹⁷ included around 17 studies in the network, whereas our NMA included 27 studies (total 29 studies) in the network with published and unpublished evidence. Secondly, these two NMAs did not include pitavastatin trials unlike our study. Pitavastatin trials contributed around 10% in the overall network and therefore increased the power of our network benefitting the other comparisons which had limited direct evidence. This shows the utility of NMA in increasing the power of the comparisons through addition of the indirect estimates to the direct estimates. Another difference between the previous NMAs and ours is in the methodology employed for fitting the model. We adopted a Frequentist analytic approach, which would be expected to yield identical results as compared with the analyses conducted within a Bayesian framework with non-informative priors as used by Naci *et al.*¹⁶ and Navarese *et al.*¹⁷

Minimizing the risk of bias is of major importance for a good quality systematic literature review. In this review, we therefore restricted the meta-analysis to RCTs, ideally with proper randomisation, allocation concealment and blinding. However, not all the studies fulfilled all of these criteria. Around 50% of the studies were at 'high' or 'unclear' RoB for attrition bias and for method employed for detection of diabetes. We included the published as well as unpublished trials, which provide good statistical power to our review. The method of detection of

diabetes varied among the trials, and we included method of detection as one of the parameters in assessment of RoB and also coloured the edges of the network according to overall bias of the study. This is to provide readers' guidance for judging the results of any comparison.

Preiss *et al.*⁴⁸ in a meta-analysis of intensive dose versus moderate dose statin found that intense dose statins were significantly associated with higher odds of diabetes to 12%. We found similar result in our pairwise meta-analysis and NMA too, atorvastatin 80 mg increased the risk of diabetes significantly compared with placebo and some of the active statin treatment. Vallejo-Vaz *et al.*⁴⁹ conducted a meta-analysis of RCTs to evaluate the effects of pitavastatin on glycaemia and new onset diabetes in non-diabetic individuals using data from 15 trials. This study found that pitavastatin decreased the risk of diabetes compared with other statin treatment; however, the association was non-significant. We also found similar results for pitavastatin compared with other equipotent statin treatments.

Recently, Swerdlow *et al.*⁵⁰ used a Mendelian randomisation approach, which is considered to be a powerful proof of causality and found single nucleotide polymorphisms (SNP) in the HMGCR gene, rs17238484 was associated with higher risk of type 2 diabetes. But limitation of this approach should also be kept in mind. The power of Mendelian randomisation lies in its ability to avoid the often substantial confounding seen in conventional observational epidemiology. This confounding can be reintroduced in Mendelian randomisation in case of linkage disequilibrium and if the selected gene has pleiotropic effect. In Swerdlow *et al.*,⁵⁰ two selected SNPs, rs17238484 and rs12916, were in strong linkage disequilibrium and have pleiotropic effect. Additionally, they, in their principal analysis with the rs17238484 SNP, found pooled OR 1.02 (95%CI: 1.00 to 1.05; $p=0.09$) for association with diabetes. Contrary to reported in the paper, this is not a significant association. They however, in their subsidiary analysis, used the rs12916 SNP and found significant association with this SNP to diabetes.

As with any evidence review, our study has some limitations. In view of the lack of head-to-head studies of statins, we performed indirect comparisons cognizant of the limitations of this approach. Use of this methodology requires assumptions about the comparability of the included RCTs with respect to similarity of patient characteristics and methodological quality. However, clinicians and patients are faced with the dilemma of choosing from among these

statins in the absence of robust comparative data about their relative safety. We found evidence of inconsistency in the atorvastatin–placebo–simvastatin atorvastatin–atorvastatin 80 mg–simvastatin triangular loops; therefore, mixed estimates related to this loop should be interpreted with caution.

We assessed the risk of diabetes across all trials and all statins for the CVDs. However, we recognize that this may be inappropriate in this case for several reasons. Different statins and existing co-morbidities may be associated with different risk profiles for developing diabetes.

For this review, we limited inclusion to RCTs and their open-label extensions. However long-term observational studies, including population-based registries, can provide realistic longer-term estimates of the risks of biologics in the ‘real world’, although they too have their limitations. These may include indication bias and differences in healthcare setting, country of origin of study, which may impact the choice of statins and make generalizability challenging.

In the context of the aforementioned limitations, our study used the best available evidence to show no potential risk of diabetes with the different classes of statins that were compared. However, large, long-term studies are required to assess this risk and the potential causes, with long-term statin use.

CONCLUSION

Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta-analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one.

CONTRIBUTORS

Literature search: D.T., S.N.
 Study design: D.T., S.N.
 Article screening: D.T., A.P., V.J., A.M.
 Data extraction: D.T., A.P., V.J., A.M.
 Data analysis: D.T.
 Data interpretation: D.T., S.N.
 Writing: D.T., S.N.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

KEY POINTS

- Statins, as a class, significantly increased the likelihood of developing diabetes by 12% in the direct meta-analysis
- High-dose atorvastatin ranked highest followed by rosuvastatin in increasing the odds of diabetes in the network meta-analysis
- Rosuvastatin increased the risk of diabetes in both, pairwise as well as network meta-analysis
- Intensive statin treatment and lipophilic statins have more likelihood of developing diabetes

PRIOR POSTINGS AND PRESENTATIONS

This topic was presented as a poster in the 20th Annual Meeting, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, USA and received ISPOR Poster Finalists Award.

RESEARCH FUNDING

None

REFERENCES

1. D’Agostino RB, Sr, Vasan RS, Pencina MJ, *et al.*. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008; **117**: 743–753.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; **360**: 7–22.
3. Shepherd J, Cobbe SM, Ford I, *et al.*. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; **333**: 1301–1307.
4. Gotto AM, Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. *Am J Cardiol* 2012; **110**: 3A–14A.
5. Colivicchi F, Guido V, Tubaro M, *et al.*. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. *Am J Cardiol* 2002; **90**: 872–874.
6. Colivicchi F, Tubaro M, Mocini D, *et al.*. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. *Curr Med Res Opin* 2010; **26**: 1277–1284.
7. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care* 2009; **32**: 1924–1929.
8. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. *Biochem J* 1993; **295**(Pt 1): 31–40.
9. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. *Metabolism* 1995; **44**: 212–217.
10. Ridker PM, Danielson E, Fonseca FA, *et al.*. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; **359**: 2195–2207.
11. Shepherd J, Blauw GJ, Murphy MB, *et al.*. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; **360**: 1623–1630.

12. Freeman DJ, Norrie J, Sattar N, *et al.* Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. *Circulation* 2001; **103**: 357–362.
13. Sattar N, Preiss D, Murray HM, *et al.* Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010; **375**: 735–742.
14. Mills EJ, Wu P, Chong G, *et al.* Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM* 2011; **104**: 109–124.
15. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. *QJM* 2012; **105**: 145–157.
16. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. *Circ Cardiovasc Qual Outcomes* 2013; **6**: 390–399.
17. Navarese EP, Buffon A, Andreotti F, *et al.* Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. *Am J Cardiol* 2013; **111**: 1123–1130.
18. Keech A, Colquhoun D, Best J, *et al.* Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. *Diabetes Care* 2003; **26**: 2713–2721.
19. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). *Ital Heart J* 2000; **1**: 810–820.
20. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 The Cochrane Collaboration; 2011.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177–188.
22. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. *J Clin Epidemiol* 2009; **62**: 857–864.
23. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013; **8**: e76654.
24. Chen F, MacCubbin D, Yan L, *et al.* Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. *Int J Cardiol* 2013; **167**: 225–231.
25. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003; **361**: 2005–2016.
26. Tavazzi L, Maggioni AP, Marchioli R, *et al.* Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; **372**: 1231–1239.
27. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. *Am J Cardiol* 1993; **72**: 1031–1037.
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; **344**: 1383–1389.
29. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002; **288**: 2998–3007.
30. Armitage J, Bowman L, Wallendszus K, *et al.* Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010; **376**: 1658–1669.
31. Athyros VG, Tziomalos K, Gossios TD, *et al.* Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet* 2010; **376**: 1916–1922.
32. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation* 2010; **121**: 306–314.
33. Downs JR, Clearfield M, Weis S, *et al.* Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998; **279**: 1615–1622.
34. Kjekshus J, Apetrei E, Barrios V, *et al.* Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007; **357**: 2248–2261.
35. Nakamura H, Arakawa K, Itakura H, *et al.* Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 2006; **368**: 1155–1163.
36. Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). *Am J Cardiol* 2014; **113**: 1593–1598.
37. Sever PS, Dahlof B, Poulter NR, *et al.* Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; **361**: 1149–1158.
38. Shen L, Shah BR, Reyes EM, *et al.* Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. *BMJ* 2013; **347**: f6745.
39. Amarenco P, Bogousslavsky J, Callahan A, 3rd, *et al.* High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006; **355**: 549–559.
40. Pedersen TR, Faergeman O, Kastelein JJ, *et al.* High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 2005; **294**: 2437–2445.
41. INTREPID: A 12-Week Study Comparing Pitavastatin 4 mg vs Pravastatin 40 mg in HIV-Infected Subjects. 2011–2013. <https://clinicaltrials.gov/ct2/show/results/NCT01301066?term=pitavastatin+AND+hiv&rank=4> [06 July 2015]
42. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. *Clin Lipidol* 2009; **4**: 291–302.
43. Kurogi K, Sugiyama S, Sakamoto K, *et al.* Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. *J Cardiol* 2013; **62**: 87–94.
44. Nozue T, Yamamoto S, Tohyama S, *et al.* Comparison of arterial remodeling and changes in plaque composition between patients with progression versus regression of coronary atherosclerosis during statin therapy (from the TRUTH study). *Am J Cardiol* 2012; **109**: 1247–1253.
45. Saito Y, Yamada N, Teramoto T, *et al.* A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. *Atherosclerosis* 2002; **162**: 373–379.
46. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolemia or combined dyslipidaemia. *Curr Med Res Opin* 2009; **25**: 2755–2764.
47. NK-104-4.01CH. 2013.
48. Preiss D, Seshasai SR, Welsh P, *et al.* Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011; **305**: 2556–2564.
49. Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, *et al.* Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. *Atherosclerosis* 2015; **241**: 409–418.
50. Swerdlow DI, Preiss D, Kuchenbaecker KB, *et al.* HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* 2015; **385**: 351–361.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web site.